e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Bronchoscopy and transthoracic ultrasound
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance.
E. Torricelli (Florence, Italy), F. Mazzoni (Florence, Italy), V. Pasini (Florence, Italy), M. Innocenti (Florence, Italy), E. Bargagli (Florence, Italy), L. Corbetta (FLorence, Italy)
Source:
International Congress 2018 – Bronchoscopy and transthoracic ultrasound
Session:
Bronchoscopy and transthoracic ultrasound
Session type:
Thematic Poster
Number:
4184
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Torricelli (Florence, Italy), F. Mazzoni (Florence, Italy), V. Pasini (Florence, Italy), M. Innocenti (Florence, Italy), E. Bargagli (Florence, Italy), L. Corbetta (FLorence, Italy). Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance.. 4184
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
Treatment strategy for patients with locally advanced and metastatic nonsmall-cell lung cancer
Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course
Year: 2011
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
Lung cancer
Source: Respipedia Article
Year: 2018
Detecting extrathoracic metastases in patients with non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 41s
Year: 2006
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Do cavitating non-small cell lung cancer patients have a more aggressive disease?
Source: Eur Respir J 2006; 28: Suppl. 50, 84s
Year: 2006
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Year: 2005
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept